What Regeneron's FY2025 10-K says: 5 signals
Regeneron filed its latest 10-K with the SEC on Feb 4, 2026. It discusses competitor named, cost reduction and joint venture.
Public (REGN)Biotechnology Research10,000+ employeesregeneron.comLinkedIn
- Filed
- Feb 4, 2026
- Period
- FY2025
- Fiscal year end
- 12/31
- Filings
- 1
10-K · latest 4
What Regeneron's 10-K filings say
- SEC EDGAR
10-K · FY2025
Filed · Fiscal year ends 12/31 · 5 signals
Libtayo royalty rate to Bristol-Myers Squibb drops from 8.0% to 2.5% from 2024-2026.
A licensing agreement modification has significantly lowered the royalty payments on worldwide sales of Libtayo from 8.0% to 2.5%.
5.5%
royalty rate reduction on worldwide Libtayo sales (from 8.0% to 2.5%)
Bristol-Myers SquibbE. R. Squibb & Sons, L.L.C.Ono Pharmaceutical Co., Ltd.
Regeneron identifies cost-effective biosimilars as a primary risk to commercial success.
The company is on high alert for competition from biosimilar products, which could be superior or more cost-effective, impacting market acceptance and revenue for its entire product portfolio.
biosimilar products
Facing patent infringement proceedings and review petitions for key drug EYLEA.
Regeneron is defending its EYLEA patents through expensive and time-consuming litigation, including inter partes reviews and post-grant review petitions.
Regeneron explicitly states that defending its intellectual property is costly and lengthy, representing a significant drain on resources and a potential risk to profitability.
Showing 4 of 5 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Regeneron with the Signal API
One POST /v1/companies/enrich call with regeneron.com returns Regeneron 10-K signals (sec-10k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"regeneron.com","signal_types":["sec-10k"],"limit":20}'Same industry
10-K at related companies
Questions about Regeneron 10-K
When did Regeneron file its latest 10-K?
What does Regeneron's latest 10-K say about cost reduction?
Where can I find Regeneron's annual report?
Source. Annual reports (Form 10-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .